- Recommendation ID
- NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide after previous treatment with abiraterone.
- Any explanatory notes
- The use of enzalutamide for treating metastatic hormone-relapsed prostate cancer previously treated with abiraterone is not covered by this guidance.
Source guidance details
- Comes from guidance
- Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
- Date issued
- July 2014
|Is this a recommendation for the use of a technology only in the context of research?||N/A|
|Is it a recommendation that suggests collection of data or the establishment of a register?||N/A|